Our data shows that this CD38-targeted, attenuated IFNα immunocytokine, dubbed “CD38-AttenukineTM”, is orders of magnitude less potent at stimulating antigen-negative cells than native IFNα, and yet maintains potent anti-tumor activity on antigen-positive cells. This evidence concerns the gene CD38 and neoplasm.